Skip to main navigation Skip to search Skip to main content

Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial

  • D Thaçi
  • , A M Soliman
  • , K Eyerich
  • , A Pinter
  • , M Sebastian
  • , K Unnebrink
  • , S Rubant
  • , D A Williams
  • , P Weisenseel
  • AbbVie Inc.
  • North Chicago
  • Department of Dermatology and Allergy
  • Technical University of Munich
  • Johann Wolfgang Goethe-University
  • Gemeinschaftspraxis für Dermatologie
  • Mahlow
  • GlaxoSmithKline Germany
  • AbbVie Deutschland GmbH & Co. KG
  • Augenklinik des Klinikums Ludwigshafen
  • Dermatologikum Hamburg and SCIderm Research Institute
  • AMEDON GmbH Lübeck

Fingerprint

Dive into the research topics of 'Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry